We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 383

Supreme Court declines to hear Eli Lilly’s “promise of the patent” appeal

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 16 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Eli Lilly Canada Inc v Novopharm Ltd

What goes upmust come down: Viagra patent invalidated by Canadian Supreme Court

  • Drinker Biddle & Reath LLP
  • -
  • Canada
  • -
  • May 13 2013

Pfizer and Teva have been fighting a legal battle over Pfizer's patent for Viagra in Canada. The first shot was fired when Novopharm Limited, now

Supreme Court of Canada denies leave to appeal in PM(NOC) judicial comity case

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • May 9 2013

The Supreme Court of Canada denied leave to appeal today from the Federal Court of Appeal ("FCA") decision in Allergan Inc. et al ats. Apotex Inc

Teva Canada Innovation v. Attorney General of Canada

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 8 2013

The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an

USTR slams Canada over the treatment of pharmaceutical patents

  • Norton Rose Canada LLP
  • -
  • Canada
  • -
  • May 6 2013

On May 1, 2013, the United States Trade Representative (“USTR”) released its annual IP report for 2013. Canada has been placed on the “Watch List"

Federal court rejects PMPRB Copaxone decision on excessive prices again

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 3 2013

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board's decision on excessive pricing of Copaxone - for the second

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

An end to generic claims for innovator profits?

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Until January 2013, the law of generic claims under section 8 of the Patent Medicines (Notice of Compliance) Regulations (the "NOC Regulations"

Authorized generics in the hypothetical world of generic damages

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada, as in other jurisdictions, links drug marketing approval with patent rights. Innovative drug manufacturers may list relevant patents against

Time for change? Potential impact of Canada’s trade negotiations on pharma patents

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Bringing a new drug to market is a costly and time-consuming endeavour. It is a process inherent with the risk of failure. In recognition of this

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy